Skip to main
CANF
CANF logo

CANF Stock Forecast & Price Target

CANF Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Can-Fite Biofarma Ltd is positioned favorably in the biopharmaceutical market, driven by its robust pipeline, particularly the drugs Piclidenoson and Namodenoson. The company is projected to achieve significant revenue growth, with risk-adjusted global sales estimated to rise from approximately $3 million in 2027 to $126 million by 2031, indicating strong market potential. The advancement of Namodenoson into Phase III trials for hepatocellular carcinoma and positive outcomes from ongoing studies further enhance the outlook for Can-Fite, highlighting the potential for breakthrough therapies in competitive indications.

Bears say

Can Fite Biofarma Ltd faces significant challenges that negatively impact its financial outlook, primarily due to the risk of unsuccessful commercialization of its products, which could hinder expected revenue growth. The company has reported a net loss of $4.9 million for the first half of 2025, with projections indicating a deeper annual loss of $10 million, raising concerns about financial sustainability. Additionally, potential delays in regulatory approvals, patient enrollment in clinical trials, and competitive pressures may further restrict the company's ability to capitalize on its therapeutic candidates and generate revenues.

CANF has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Can-Fite BioPharma Ltd. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Can-Fite BioPharma Ltd. (CANF) Forecast

Analysts have given CANF a Strong Buy based on their latest research and market trends.

According to 2 analysts, CANF has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Can-Fite BioPharma Ltd. (CANF)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.